Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance

Adaptive Biotechnologies Corp
Invesco S&P 500 High Div Low Volatility ETF

Price performance

Price movement over the last 24 hours

Key statistics

Adaptive Biotechnologies Corp vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Invesco S&P 500 High Div Low Volatility ETF trades at $51.59. Which is the better fit depends on your goals.

ADPTSPHD
Market Cap
$3.33B
Sector
Health
52-Week High
$22.37$52.63
52-Week Low
$10.24$46.96
Enterprise Value
$3.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Invesco S&P 500 High Div Low Volatility ETF

SPHD trades at $51.64, down 0.92% today, with a bullish technical outlook supported by moving averages and strong trend indicators. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering a 4.5% SEC yield with monthly distributions. Recent news highlights its role in retirement income strategies, though long-term performance has trailed the broader market.

The outlook for SPHD is cautiously positive for income-focused investors seeking stability, with technical strength and defensive positioning. Key risks include underperformance during bull markets and sensitivity to interest rate changes. Analyst sentiment is mixed, balancing yield appeal against growth limitations.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Invesco S&P 500 High Div Low Volatility ETF

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.

Read more on SPHD